Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 16/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3552009 | 0.88 | FFAR1 (0.65) | FFAR1PPARGCYP26A1CYP3A4CYP26B1 | |
| SCHEMBL3548095 | 0.88 | FFAR1 (0.65) | FFAR1PPARGCYP26A1CYP3A4CYP26B1 | |
| SCHEMBL3548092 | 0.88 | FFAR1 (0.65) | FFAR1PPARGCYP26A1CYP3A4CYP26B1 | |
| SCHEMBL13318324 | 0.86 | FFAR1 (0.56) | FFAR1PPARGCYP26A1CYP3A4CYP26B1 | |
| SCHEMBL13318326 | 0.84 | FFAR1 (0.53) | FFAR1PPARGCYP26A1CYP3A4CYP26B1 | |
| SCHEMBL13318325 | 0.84 | FFAR1 (0.53) | FFAR1PPARGCYP26A1CYP3A4CYP26B1 | |
| SCHEMBL13318270 | 0.82 | FFAR1 (0.56) | FFAR1PPARGCYP26A1CYP3A4CYP26B1 | |
| SCHEMBL13318446 | 0.82 | FFAR1 (0.56) | FFAR1PPARGCYP26A1CYP3A4CYP26B1 | |
| SCHEMBL3550565 | 0.81 | FFAR1 (0.60) | FFAR1PPARGCYP26A1CYP3A4CYP26B1 | |
| SCHEMBL3547589 | 0.81 | FFAR1 (0.60) | FFAR1PPARGCYP26A1CYP3A4CYP26B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7687526-B2 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687526-B2 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | GOT2, PC, GLS2 | FFAR1 549/4885PPARG 14/4885CYP26A1 170/4885 |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | GOT2, GLS2, PC | FFAR1 699/4885PPARG 16/4885CYP26A1 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.